deltatrials
Completed PHASE1 NCT00028535

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Phase I Trial of Interleukin-12 in Combination With Paclitaxel Plus Herceptin in Patients With Her2-positive Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions Male Breast Cancer Recurrent Breast Cancer Recurrent Endometrial Carcinoma Recurrent Gastric Cancer Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Small Cell Lung Cancer
Interventions paclitaxel recombinant interleukin-12 trastuzumab
Updated 6 times since 2017 Last updated: Jun 3, 2013 Started: Nov 30, 2001 Primary completion: Feb 28, 2009

Listed as NCT00028535, this PHASE1 trial focuses on Male Breast Cancer and Recurrent Breast Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Columbus, United States